Parikh A, et al. - In this open-label, single arm phase-2 study, researchers evaluated CTLA-4 and PD-1 blockade with radiation (XRT) as a strategy to stimulate an immune response for patients with pancreatic ductal adenocarcinoma (PDAC). For this investigation, 25 metastatic PDAC patients in an exploratory cohort were enlisted. Treatment consisted of ipilimumab (1 mg/kg every 6 wks), nivolumab (240 mg every 2 wks) and 3 fractions of 8 Gy of XRT at cycle 2. Eligibility criteria included patients who had histologically-confirmed PDAC, ECOG PS 0-1, and progression on at least 1 line of tx. In patients with metastatic PDAC, dual blockade of CTLA-4 and PD-1 with XRT is feasible and shows promising activity. The most common adverse events included elevated lipase, lymphopenia, fatigue, hyperglycemia, mucositis and hepatitis.